GSK PLC

GSK

Equity

ISIN US37733W2044 / Valor 120042705

New York Stock Exchange, Inc (2024-09-16)

USD 43.55+1.26%

GSK PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

GSK PLC is a focused biopharma company that prevents and treats diseases with vaccines, specialty, and general medicines. Their portfolio includes over 150 primary care products supplied in 112 countries worldwide, as well as specialty medicines focused on infectious diseases, HIV, respiratory/immunology, and oncology. GSK is a leader in infectious diseases and HIV innovation, with a broad vaccines portfolio targeting infectious diseases at every stage of life. Their Ahead Together strategy aims to intervene early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

GSK PLC reported a significant increase in total sales for the second quarter of 2024, reaching £7.9 billion, which represents a 13% growth at constant exchange rates (CER). This growth was driven by strong performances across various segments, including Specialty Medicines and General Medicines.

Specialty Medicines

Specialty Medicines sales saw a remarkable 22% increase in Q2 2024. Notably, HIV sales grew by 13%, and Oncology sales more than doubled, reaching £0.4 billion. This segment's robust performance underscores the successful launch of new products in these therapeutic areas.

Core Operating Profit

GSK PLC's core operating profit for Q2 2024 increased by 18% at CER, with a further positive impact of 3% excluding COVID-19 solutions. This growth was attributed to strong sales leverage and a favorable product and regional mix, despite increased investments in R&D and growth assets.

Dividend Declaration

Reflecting its strong business performance, GSK PLC declared a dividend of 15p per share for Q2 2024. The company continues to expect a full-year dividend of 60p per share, maintaining its dividend policy and expected payout ratio.

Upgraded Guidance

GSK PLC upgraded its full-year 2024 guidance, now expecting turnover growth of 7% to 9% at CER, up from the previous 5% to 7%. Core operating profit growth is anticipated to be between 11% to 13%, and core earnings per share are expected to increase by 10% to 12%, reflecting the company's strong operational execution and portfolio strength.

Summarized from source with an LLMView Source

Key figures

16.4%1Y

-10.9%3Y

-14.2%5Y

Performance

20.4%1Y

23.6%3Y

24.5%5Y

Volatility